ArticleLeukemia2018

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.

K Kondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.